Immune drug nivolumab takes on returning prostate cancer
NCT ID NCT03637543
First seen May 27, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can control the disease by lowering or stabilizing PSA without the cancer spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
DFCI Londonderry
Londonderry, New Hampshire, 03053, United States
-
DFCI South Shore
South Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
St. Elizabeth's Medical Center
Boston, Massachusetts, 02135, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If it works, this could point toward a new immune-based treatment option for men with prostate cancer that has returned after initial therapy.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. Nivolumab can cause immune-related side effects, and it may not effectively control PSA levels or slow cancer growth.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.